Singapore S*BIO Inks "One Of The Biggest" Biotech Deals in Asia With Onyx For JAK2 Inhibitors

PERTH, Australia - Singapore-based S*BIO inked a development collaboration and option and license agreement with Onyx Pharmaceuticals for S*BIO's two JAK2 inhibitors SB1518 and SB1578, S*BIO announced Jan. 6